SHANGHAI, January 23, 2024/PRNewswire/ -- On January 19, 2024, the first best communication case in the biomedical industry was revealed in Shanghai, co-sponsored by BioPR, R&D, and Zhangjiang Pharmaceutical Valley, and supported by Shangfang Group's “Zhang Jiang Zhishang” and ZJ-BBC. Mengke Pharmaceutical wonGold Award for Best Corporate Video of the Year,Best Product Communication Case Award of the Year.
“This is a terrible war for life.” Since the day antibiotics were discovered, the problem of bacterial drug resistance has also followed. Bacteria have continued to evolve, yet the pace of human discovery of antibiotics has experienced a short vacuum period in the past ten years or so. Since its establishment in 2007, League Science has been actively developing various key areas such as drug-resistant gram-positive bacteria, drug-resistant gram-negative bacteria, and mycobacterium non-tuberculosis to become a pioneer in the field of infection.
In June 2021, the core product of Mengke Pharmaceutical, contizolamide tablets (Uxitai)) Listed domestically, it was included in the medical insurance catalogue only half a year after approval. December 2023, UxitaiThe medical insurance contract was successfully renewed at the original price for a period of two years. In these two and a half years, contizolamide tablets quickly covered patients in need, helped doctors address unmet clinical needs, and built up a good reputation in the industry.
In the future, Mengke Pharmaceutical will continue to adhere to the concept of “using good medicine and seeking good results”, accelerate research and development of new drugs, so that more patients can use new drugs and good drugs. At the same time, it will use various means to popularize knowledge about bacteria and antimicrobials to the public, assume corporate social responsibility, and build the last line of defense for humans against drug-resistant bacteria.
About Mengke
Established in 2007, it is an innovative biomedical enterprise centered on treating infectious diseases, with global independent intellectual property rights and international competitiveness. It is committed to discovering, developing and commercializing innovative drugs that do not meet clinical needs. Since its inception, the company has been adhering to the concept of “seeking good results with good medicine”, focusing on the increasingly serious problem of bacterial drug resistance around the world, solving clinical problems and differentiated innovation as its core competitiveness. The goal is to provide more effective and safer treatment options for the most common and serious clinically resistant bacterial infections. For more information, please visit the official website of Mengke Pharmaceuticals or subscribe to Mengke Pharmaceuticals China's official WeChat account.